7,451.50

+49.50

+0.67%

51,933.00

+548.00

+1.07%

27,222.00

+136.75

+0.50%

Russell 2000 Futures

2,801.00

+40.50

+1.47%

4.8590

+0.0220

+0.45%

23.62

-2.02

-7.89%

4,116.00

+41.10

+1.01%

74,364.82

-1,507.66

-1.99%

Crude Oil Dec 26

87.87

-2.96

-3.26%

US Private Equity

10,772.76

+11.83

+0.11%

NasdaqCM - Nasdaq Real Time Price USD

Bolt Biotherapeutics, Inc. (BOLT)

6.54 +0.16 (+2.51%)

At close: November 6 at 4:00:01 PM EST

Loading Chart for BOLT

Chart Range Bar

Interval:

In partnership with ChartIQ

Bolt Biotherapeutics to Participate in Upcoming Conferences

Bolt Biotherapeutics to Participate in Upcoming Conferences

Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications

Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates

Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates

Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates

Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates

Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates

Bolt Biotherapeutics Inc.: Q3 Earnings Snapshot

Bolt Biotherapeutics Inc.: Q3 Earnings Snapshot

Metastatic HER2-Positive Breast Cancer Market Expected to Surge at a CAGR of 8.3% During the Forecast Period (2026–2036) Due to Advancing Targeted Treatments | DelveInsight

Metastatic HER2-Positive Breast Cancer Market Expected to Surge at a CAGR of 8.3% During the Forecast Period (2026–2036) Due to Advancing Targeted Treatments | DelveInsight

Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Beats Revenue Estimates

Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Beats Revenue Estimates

Adaptive Biotechnologies (ADPT) Q3 Earnings and Revenues Top Estimates

Adaptive Biotechnologies (ADPT) Q3 Earnings and Revenues Top Estimates

Mobilize your Website

View Site in Mobile | Classic

Share by: